Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 426-432

  Nakazato, T ^a   Kanuma, T ^a   Tamura, T ^a   Faried, L S ^a   Aoki, H ^a   Minegishi, T ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Clear cell adenocarcinoma; Human epithelial ovarian cancer; Sperm protein 17

Indexed keywords

PACLITAXEL; PROTEIN DERIVATIVE; SMALL INTERFERING RNA; SPERM PROTEIN 17; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY;

ADENOCARCINOMA, CLEAR CELL; ANTIGENS, SURFACE; CARRIER PROTEINS; CELLS, CULTURED; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 33947239334     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00815.x     Document Type: Article

References (32)

1. Ioka A, Tsukuma H, Ajiki W, Oshima A. Ovarian cancer incidence and survival by histologic type in Osaka, Japan. Cancer Sci 2003;94:292-6.
2. The Research Group for Population-Based Cancer Registration in Japan. Cancer incidence in Japan. In: Tsukuma H, Ajiki W, Oshima A, eds. Cancer mortality and morbidity statistics: Japan and the world - 2004. Basel, Switzerland: Karger, 2004:95-130.
3. Kita T, Kokuchi Y, Hirata J et al. Prognosis of ovarian cancer today. Cancer J 1998;11:201-7.
4. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of ovary. Cancer 2000;88:2584-9.
5. Okugawa K, Hirakawa T, Fukushima K et al. Relationship between age, histological type, and size of ovarian tumors. Int J Gynaecol Obstet 2001;74:45-50.
6. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-9.
7. Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of ovary: a study of 59 cases. Gynecol Oncol 1989;35:199-203.
8. O'Brien ME, Schofield JB, Tan A, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49:250-4.
9. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
10. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-7.
11. Behbakht K, Randall TC, Benjamin I, Morgan MA, Kings S, Rubin SC. Clinical characteristics of clear cell carcinoma of ovary. Gynecol Oncol 1998;70:255-8.
12. Enomoto T, Kuragaki C, Yamasaki M et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and cisplatin?. Proc Am Soc Clin Oncol 2003;22:447.
13. Elbashir SM, Harborth J, Landeckel W, Yalcin A, Weber K, Tsuchl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
14. Elbashir SM, Landeckel W, Tsuchl T. RNA interference is mediated by 21-22-nucleotides RNAs. Genes Dev 2001;15:188-200.
15. Straughn JM, Shaw DR, Guerrero A et al. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004;108:805-11.
16. Richardson RT, Yamasaki N, O'Rand MG. Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction. Dev Biol 1994;165:688-701.
17. Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 (SP17) is a novel cancer-testis antigen in multiple myeloma. Blood 2001;97:1508-10.
18. Chiriva-Internati M, Wang Z, Salati E, Wroblewski D, Lim SH. Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 2002;94:2447-53.
19. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (SP17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002;100:961-5.
20. Wen Y, Richardson RT, Widgren EE, O'Rand MG. Characterization of SP17: a ubiquitous three domain protein that binds heparin. Biochem J 2001;206:113-22.
21. Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood 2001;98:2160-5.
22. Wen Y, Richardson RT, O'Rand MG. Processing of the sperm protein SP17 during the acrosome reaction and characterization as a calmodulin binding protein. Biochem J 1999;357:25-31.
23. Lea IA, Richardson RT, Widgren EE, O'Rand MG. Cloning and sequencing of cDNA encoding the human sperm protein, SP17. Biochem Biophys Acta 1996;1307:263-6.
24. Frayne J, Hall L. A re-evaluation of sperm protein 17 (SP17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction 2002;124:767- 74.
25. Lea IA, Widgren EE, O'Rand MG. Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol 2004;2:57-63.
26. Carr DW, Fujita A, Stentz CL, Liberty GA, Olson GE, Narumiya S. Identification of sperm-specific proteins that interact with A-kinase anchoring proteins in a manner similar to the type II regulatory subunit of PKA. J Biol Chem 2001;276:17332-8.
27. Hasegawa K, Ono T, Matsushita H et al. A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis. Int J Cancer 2004;108:86-90.
28. Reed F, Yu JJ, Davis A, Gannon J, Armentrout SL. Clear cell tumor have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003;9:5299-305.
29. Schwartz DR, Kardia SH, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian cancer. Cancer Res 2002;62:4722-29.
30. Lancaster JM, Dressman HK, Whitaker RS et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004;11:51-9.
31. Spentzos D, Levine DA, Romani AM et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
32. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004;191:1552-72.